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To identify cost-of-illness studies of Type 1 diabetes mellitus (Type 1 DM) in the United 
Kingdom (UK) and review this literature to estimate the current cost of Type 1 DM to the UK 
National Health Service. 
 
Methods 
Bibliographic databases and grey literature were systematically searched to identify all 
published and unpublished reporting of the costs of Type 1 DM in the UK.  Studies were 
excluded if they did not present cost information from the UK or did not disaggregate 
information by diabetes type.  Three grey literature sources and 11 published studies were 
identified for inclusion in the literature review. 
 
Results 
The included studies and reports covered topics including the overall cost of Type 1 DM, 
costs of individual diabetic complications and costs of specific interventions for Type 1 DM.  
The most recent published estimate of the cost of Type 1 DM was over 15 years old, and 
although this estimate has been inflated to current prices the estimate is not adjusted for 
changes to treatment pathways over this period and is therefore not considered an accurate 
estimate of current costs of Type 1 DM. 
 
Conclusions 
There is not a recently published estimate of the cost of Type 1 DM in the UK therefore it is 
recommended that an up-to-date national, comprehensive COI study should be conducted.  
Recommendations for the format of this study are made, including extending the scope to 





Keywords:  diabetes, type 1 diabetes, cost, cost-of-illness, economic 
 
JEL codes:  I10 – General Health 





Insulin treatment, regular screening for and treatment of long-term complications in Type 1 
diabetes mellitus (Type 1 DM) result in costs to patients, carers, and the National Health 
Service (NHS) in the United Kingdom (UK).  Scientific research priorities are set using a 
range of criteria and the burden of disease is often used to consider priority areas for 
research funding [1].  Type 1 DM has not been a specific research priority in the UK to date.  
There has instead been a focus on the costs associated with the increasing prevalence of 
Type 2 diabetes mellitus (Type 2 DM) and with the burden presented by diabetes as a whole 
[2, 3].  Ettaro et al [4] estimated that 3% of the UK population have diabetes (all types) but 
that it consumes more than 9% of the NHS budget, and Currie & Peters [5] estimated that all 
diabetes and its complications consume more than 5% of NHS annual expenditure. 
 
The cost issues of Type 1 DM differ from those of Type 2 DM as all patients with Type 1 DM 
consume insulin-replacement resources throughout their lifetimes whereas Type 2 DM can 
often be prevented and/or treated with lifestyle modification alone.  Type 1 DM also results in 
higher rates of hospitalisation for ophthalmic and renal complications compared with Type 2 
DM [6].  This study focuses on the costs of Type 1 DM specifically as this area represents a 
gap in the national research agenda.  Quantifying clear costs of Type 1 DM and 
disentangling the costs associated with the two main types of diabetes would contribute to 
several areas of healthcare provision and research in the UK.  Overall cost burden estimates 
would support research funders to compare levels of funding for different disease areas to 
the distribution of costs to the NHS and to wider society of the same diseases.  Disease-
level cost estimates would also support commissioners at the strategic national level to 
consider whether the levels of expenditure for prevention and treatment of diseases are 
appropriate, for example by informing programme budgeting.  The NHS reported that in 
2009/10 £1.4 billion was spent on the diabetes care programme in England, compared to 
£2.5 billion on coronary heart disease care and £5.8 billion on cancer care [7].  The NHS 
Programme Budgeting data [7] do not include a breakdown of costs by type of diabetes 
therefore there is no guidance for commissioners regarding the allocation of diabetes 
resources between care programmes for the different types of diabetes.   
 
Evidence which disentangles these top level costs would also be useful to the research and 
healthcare communities.  For example, unit cost and unit resource use estimates would be 
valuable for use in cost-effectiveness models to support National Institute for health and 
Clinical Excellence (NICE) appraisals and in health technology assessment more widely. 
Healthcare trusts are also likely to benefit from clearer unit-level costs, which could be used 
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to assist in planning investments and in drawing up business cases for new healthcare 
technologies. 
 
From a health economic perspective any chronic disease will incur several different types of 
costs.  For Type 1 DM in the UK these include direct costs of treatment to the NHS (e.g. 
insulin), direct costs of complications to the NHS (e.g. Angiotensin-converting enzyme (ACE) 
inhibitors for nephropathy), indirect costs (including travel time and productivity losses) and 
intangible costs to the patients (e.g. pain and suffering associated with treatment). 
 
Information on the cost of Type 1 DM can be identified from cost-of-illness (COI) studies or 
economic evaluations of particular interventions for the disease.  COI is “…a method of 
calculating the resources used to prevent, detect, and treat a disease, in absolute terms...” 
[8] and is used to estimate the total cost of an illness in a specified healthcare setting.  
Economic evaluation involves the comparative analysis of alternative healthcare 
interventions in terms of both their costs and benefits [9]. 
 
The aims of the current study are to identify and critically appraise all previous COI studies 








2.1. Literature search 
 
A search of published literature was conducted in March 2010 using the following 
bibliographic databases: Cochrane Database of Systematic Reviews via Cochrane library; 
DARE via Cochrane library; Health Technology Assessment via Cochrane library; NHS 
Economic Evaluation Database; EMBASE via Ovid; MEDLINE via Ovid 1948 to March 2010; 
PsychInfo via Ovid.  The search used a combination of MeSH headings and free text key 
terms relating to Type 1 DM.  The Scottish Intercollegiate Guidelines Network search filter 
for economic studies SIGN [10] was included to specify economic studies rather than other 
study designs of Type 1 DM.  The full list of search terms is presented in Figure 1.  The 
search covered a range of dates from the 1940s through to 2010.   
 
Fig.1 Bibliographic database search strategy 
 
A two-stage screening process was conducted using pre-specified inclusion and exclusion 
criteria.  Firstly a reviewer screened the titles and abstracts of the search results for 
potentially relevant studies then the full manuscript of all potentially relevant studies was 
retrieved and assessed.  A study was included if it reported UK-specific information on the 
costs of diabetes and reported Type 1-specific information separately from Type 2 
information.  Studies were excluded if they did not present cost information from the UK, did 
not disaggregate information by diabetes type, or were published in a language other than 
English.  Economic evaluations were excluded unless they reported estimates of absolute 
annual or lifetime costs of interventions.  The bibliographies of review studies that reported 
relevant results (i.e. UK setting and Type 1-specific results) were searched and pertinent 
primary studies were added to the review. 
 
Grey literature was also searched to identify unpublished data on the costs of Type 1 DM.  
Online resources of relevant government, NHS and diabetes-related organisations [11-24] 
were accessed in July and August 2010 and searched for any information regarding the cost 
of Type 1 DM in the UK.  Grey literature was only deemed relevant if it presented UK data 
split by diabetes type.   
 
Epidemiological data on the incidence and prevalence of Type 1 DM was included if it was 
identified whilst searching for cost data in the grey literature.  These burden-of-illness 
estimates were included in the review so that if an estimate of the cost per patient of Type 1 
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DM was identified this could be combined with epidemiological data to estimate population 
level costs.   
 
2.2. Review methodology 
 
For each included study a single reviewer extracted data relating to the aims of the study, 
the study design, the setting, the data sources used and any reported characteristics of the 
population for which costs were estimated, the methods used to estimate costs, the types of 
cost included (e.g. direct or indirect; overall cost or cost of individual diabetic complications), 
and the results in terms of estimated unit costs, overall costs, and any epidemiological 
results. 
 
Each included study was critically appraised based on the methodological framework 
outlined by Pagano et al [25].  This focused on definition of diabetes, the epidemiological 
approach, the perspective of the analysis, how resource use was estimated, how unit costs 
were valued, whether sensitivity analyses were conducted, and how results were presented. 
 
Although the review was not a full systematic review it did fulfil items 3, 6-9, 17, and 24-26 of 
the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) 2009 
[26]. 
 
2.3. Data Analysis 
 
Data on annual costs of Type 1 DM was extracted from each included paper.  Where 
multiple categories of costs were reported (e.g. drug costs and costs of contacts with 
healthcare practitioners) all the categories were extracted. 
 
In order to estimate the current cost of Type 1 DM, each cost data item from the included 
papers was inflated to 2010-11 prices using Hospital & Community Health Services (HCHS) 
inflation indices from the Personal Social Services Research Unit (PSSRU) [27].  The cost in 
2010-11 was calculated as the ratio of the HCHS Pay & Prices Index for 2010-11 to the 
HCHS Pay & Prices Index for the year of the published cost, multiplied by the published 








3.1. Summary of evidence 
 
The search strategy returned a total of 2,107 records, of which nine fully met the inclusion 
criteria.  The majority of the papers excluded as not being relevant to the UK were from non- 
European countries (n = 82, mostly US) and 35 were from non-UK European countries.  
Details of studies excluded at the full paper stage can be found in Appendix A.  Five relevant 
reviews were also identified and two additional studies meeting the inclusion criteria were 
identified from their bibliographies, giving a total of 11 published studies that were included 
in the review (see Figure 2 and Table 1).  Three grey literature sources also reported data 
relevant to the review [17, 28, 29].  All the studies used prevalence-based methods to report 
information about the cost of Type 1 DM for a specific annual period. 
 
Three published studies provided estimates of the overall cost of Type 1 DM [8, 30, 31], 
three estimated the cost of a single diabetic complication only [32-34], two estimated the 
total costs of prescribing for Type 1 DM [5, 35], and one estimated the costs of insulin 
treatment [36].  Two published studies [37, 38] and one grey literature report [28] estimated 
the cost of insulin pumps and two further grey literature sources provided evidence on the 
epidemiology of Type 1 DM but not costs [17, 29]. 
 
Fig.2 Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) 
flowchart of study selection process 
 
3.2. Epidemiology of Type 1 DM in the UK 
 
Of the 11 included published studies, six did not include any estimate of the incidence or 
prevalence of Type 1 DM in the UK [5, 30-32, 36, 37].  Of the remaining five studies, one 
reported an incidence rate of 19.3 per 10,000 patient years [38], and the others reported 
prevalence rates of 1.84 [8], 2.40 [35], and 2.67 per 1,000 people [33, 34].  The 2010 
population of the UK has been estimated by the Office for National Statistics as 62,262,000 
[39].  Combining this value with the prevalence rates reported in the four studies results in 





Two of the included grey literature sources [17, 29] provided information on the epidemiology 
of Type 1DM.  However, a nationally accepted estimate of the prevalence or incidence of 
Type 1 DM in the UK was not identified.  The Association of Public Health Observatories 
(APHO) Diabetes Prevalence Model [29] was identified as the most up to date estimate of 
overall diabetes prevalence in the UK [Yorkshire and Humber Public Health Observatory 
personal communication 2010]; however this tool did not split results by diabetes type.  de 
Lusignan et al [40] developed an algorithm to estimate the prevalence of Type 1 DM using 
data from the CONDUIT [41] and QICKD [42] studies which was recommended by the 
Yorkshire and Humber Public Health Observatory (YHPHO) [personal communication 2010] 
as the most robust current evidence regarding the proportion of people with diabetes that 
have Type 1.  A weighted average of Type 1 DM prevalence rates was estimated as 6.08% 
of all people with diabetes.  Applying this weighted average to overall prevalence estimates 
from the APHO Model resulted in an estimate of 219,337 adults aged over 16 years with 
Type 1 DM in the UK in 2010.  This estimate falls within the estimated prevalence range 
reported by Diabetes UK of 5-15% of 2.8 million people diagnosed with diabetes, equating to 
140,000 to 420,000 people with Type 1 DM in the UK in 2010 [17].  However, the estimate is 
higher than implied by the prevalence rates reported in published studies. 
 
3.3. Overall cost of Type 1 DM in the UK 
 
Gray et al [8] reported a bottom-up COI study in England and Wales using a diabetic cohort 
generated from incidence data from Oxford, England.  The study included direct costs of 
treatment of Type 1 DM and its complications, costs of informal care, and indirect costs in 
the form of productivity losses.  Unit costs published by the Department of Health and the 
Office of Health Economics (at 1992 prices) were combined with incidence data from the 
Oxford-generated cohort and resource use data from a US study of hospitalisation rates.  
The estimated total population with Type 1 DM in England and Wales in 1992 was 93,581.  It 
was estimated that this cohort incurred direct costs of £95.6 million (sensitivity analyses 
range £77 million to £113 million) and indirect costs of £113 million (see Table 2).  Currie & 
Peters [30] published a letter in response to Gray et al suggesting that their reported annual 
cost was a significant underestimate.  In particular, the estimate of the number of in-patient 
admissions and their costs were considered low, based on comparison with Welsh data 
collected by Currie & Peters.  This data suggested that in-patient treatment for Type 1 DM in 
England and Wales cost approximately £180 million annually, and insulin and monitoring 
cost approximately £45 million annually.  These figures would lead to a substantially higher 




Currie et al [31] used a self-report survey to estimate that Type 1 DM cost an average of 
£3,224 (2005 prices) per patient per year in Wales.  A population level cost estimate was not 
provided.  The per-patient cost reported by Currie et al of £3,224 is very high in comparison 
to the costs reported by Gray et al [8], which equate to approximately £1,022 per patient per 
year.  The difference is likely to be due to Currie et al’s cohort being older with a longer 
duration of diabetes.  This cohort was therefore likely to have higher rates of diabetic 
complications than Gray et al’s hypothetical cohort, leading to the higher per-patient cost 
estimate.  Unfortunately this hypothesis cannot be tested as the assumptions about rates of 
diabetic complications were not reported by Gray et al.  Due to the atypical nature of the 
Currie et al cohort we did not combine their per-patient estimate with reported prevalence 
rates to give a population level estimate. 
 
Several estimates of the total cost of diabetes overall in the UK were identified from the grey 
literature.  National governmental bodies such as the Department of Health, the NHS, and 
HM Treasury all provide estimates of the overall cost of diabetes [7, 21, 24].  Despite these 
abundant sources, no estimate of the cost of Type 1 DM specifically was identified.  National 
governmental and charitable bodies have thus far neglected to report the cost of diabetes 
split by diabetes type. 
 
3.4. Cost of complications of Type 1 DM in the UK 
 
Four studies were identified that estimated the cost of individual diabetic complications: two 
for severe hypoglycaemia [32, 33], one for diabetic neuropathy [31] and one for diabetic 
nephropathy [34].  No studies were identified that estimated the cost of other diabetic 
complications (see Table 3). 
 
Two studies estimated the cost of severe hypoglycaemia in the UK.  Leese et al [33] used 
prevalence data from the Diabetes Audit and Research in Tayside Scotland/Medicines 
Monitoring Unit (DARTS/MEMO) Collaboration and cost data from the Information Statistics 
Division cost book to estimate the annual cost of severe hypoglycaemia in the UK as ≤ £13 
million.  The cost results were not reported by diabetes type, but if it is assumed that an 
episode of severe hypoglycaemia costs the same for both main types of diabetes then we 
can estimate that severe hypoglycaemia in Type 1 DM cost ≤ £6 million in the UK in 1997-
98.  Hammer et al. [32] conducted a cost analysis based on a survey of 639 patients in 
Spain, Germany and the UK that asked diabetes patients about their consumption of 
healthcare resources. By combining this data with published unit costs the authors estimated 
the total cost per severe hypo event for Type 1 DM patients in the UK in 2007 as ranging 
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from £37 to £887 (including direct costs during and following the severe hypoglycaemic 
event and indirect productivity loss costs).  Population level cost estimates were not 
provided. 
 
Currie et al [31], described above, provides data to suggest that the annual per-patient cost 
of diabetes increases with increasing severity of diabetic peripheral neuropathy.  However, 
these results were not split by diabetes type so an estimate of the cost of peripheral 
neuropathy in Type 1 DM was not possible.  
 
Gordois et al [34] constructed a prevalence-based COI model to estimate the annual cost of 
diabetic nephropathy in the USA and UK in 2001.  The number of people diagnosed with 
diabetes and the number of people experiencing different nephropathy health states 
(microalbuminuria, overt nephropathy, end-stage renal disease and kidney transplant) were 
estimated from published data on diabetes prevalence and complication rates.  These 
prevalence estimates were combined with published resource use and unit cost data from 
the USA and UK to estimate the total annual cost of diabetic nephropathy in each country.  
The model considered direct costs only and focussed on costs incurred in excess of what a 
person with diabetes but no nephropathy would incur.  The total annual cost to the NHS of 
nephropathy in Type 1 DM in 2001 was estimated at £152 million (sensitivity analysis range 
£115 to £239 million).  The model estimated that 12% of people with diabetes have Type 1 
DM, but that Type 1 DM patients account for 20% of the total costs of diabetic nephropathy. 
 
3.5. Cost of interventions for Type 1 DM in the UK 
 
Two studies [5, 35] investigated the total costs of prescribing for Type 1 DM using healthcare 
provider prescribing data.  Currie & Peters [5] analysed Welsh prescribing data to estimate 
the cost of drugs that directly affect glucose metabolism (not drugs to treat complications of 
diabetes).  They estimated that drugs for Type 1 DM cost on average £468 per patient year 
(1993-94 prices).  Population level cost estimates were not reported by diabetes type.  
Evans et al [35] used DARTS/MEMO Collaboration data to estimate the cost of all drugs 
prescribed to patients diagnosed with diabetes (including drugs to treat diabetic 
complications).  Type 1 diabetic patients accounted for 0.8% of total prescribing costs in 
Tayside, equating to approximately £246 per patient.  This estimate is lower than that of 
Currie & Peters, which is surprising given that Evans et al were considering a wider range of 
drugs.  Differences may be partly explained by the different region-specific cost sources 
used in the studies.  Based on the total prescribing costs of the NHS, the authors suggest 
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that the total cost of drugs for Type 1 diabetic patients in 1995 in the UK was £36 million 
(£22 million for anti-diabetic drugs and £14 million for other drugs). 
 
One study specifically investigated the cost of insulin for treatment of Type 1 DM: Poole et al 
[36] conducted a cost comparison of insulin glargine and insulin detemir in the UK and 
estimated the annual cost of treatment with glargine in 2004 as £1,198 per person and with 
detemir as £1,330 per person.  These costs differ from anti-diabetic costs estimated by 
Currie & Peters [5] as the latter study was conducted before insulin detemir or glargine had 
been launched.  Currie & Peter’s analysis also excluded pen injectors and needles, whereas 
Poole et al conducted a more comprehensive analysis including all insulin delivery devices, 
testing strips, and sharps.  Absolute population-level costs were not reported. 
 
One NICE technology appraisal [28], one Health Technology Assessment (HTA) report [37], 
and one published study [38] were identified that provided information on the cost of 
continuous subcutaneous insulin infusion (CSII) for Type 1 DM.  The NICE technology 
appraisal [28] did not present population-level estimates of total annual costs.  The 
associated costing report [43] estimated the annual per-patient cost of providing CSII in 
England in 2007-08 as £1,788.  This equates to a total cost of nearly £25 million to provide 
pump therapy in all of England, taking into account savings from not providing multiple daily 
injections to pump patients.  The HTA report [37] conducted a meta-analysis to estimate the 
per-patient annual cost of insulin pump therapy as £3,602 - £3,878.  The cost to the NHS in 
England and Wales at 2001-02 prices was estimated as £3.5 million if 1% of Type 1 DM 
patients used insulin pumps, £10.5 million if 3% uptake and £17.5 million if 5% uptake.  
Feltbower et al [38] investigated the financial impact on Primary Care Trusts (PCTs) of 
providing insulin pumps to children aged under 15 years and estimated that the additional 
expense for a single PCT of providing insulin pumps at 2001-02 prices was £400-£1,300 if 
1% of children received pumps, and £2,100 - £6,600 at a 5% take-up rate. 
 
3.6. Current costs of Type 1 DM 
 
Using HCHS inflation indices from the PSSRU [27], cost values from the Type 1 DM COI 
literature were inflated to 2010-11 prices to give an estimate of current costs of Type 1 DM.  
Using this method we estimated the total direct annual cost of Type 1 DM in England & 
Wales in 2010-11 as approximately £175.4 million based on Gray et al [8].  This figure 
includes hospital, GP, and insulin costs directly attributable to Type 1 DM as well as to 
vascular, ophthalmic, neurological, and renal complications.  Indirect costs as a result of 
productivity losses were estimated from Gray et al [8] to be just over £207 million, and 
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informal care costs were estimated at just over £20 million.  These estimates derive from 
simple inflation of the costs reported in Gray et al [8].  Due to the age of this study the 
estimates may not adequately reflect current costs of Type 1 DM due to changes in 
treatment pathways for Type 1 DM, changes in prices of resource items (e.g. drugs coming 
off patent), and changes in costs of healthcare practitioner time and hospital admissions.  
This is a major limitation of the body of published Type 1 DM COI evidence and of the 
estimates presented in the current study. 
 




4. DISCUSSION AND CONCLUSIONS 
 
Eleven published studies and three grey literature sources reporting information on the 
burden and costs of Type 1 DM in the UK were reviewed.  Studies used COI methods to 
estimate the direct and indirect costs of all of Type 1 DM, the costs of individual diabetic 
complications, and the costs of specific interventions for Type 1 DM.  The review estimated 
the direct costs to the NHS of treating Type 1 DM in England and Wales to be more than 
£175 million in 2010-11.  However, this figure has been inflated from a study published more 
than 15 years ago without any adjustment for changing treatment paradigms or cost of 
individual treatments over this time period. 
 
4.1. Limitations of published studies 
 
Very little information on the epidemiology and cost of Type 1 DM was identified from the 
grey literature.  Governmental and non-government organisations alike failed to report cost 
estimates split by diabetes type.  Type 1 and Type 2 DM are distinct illnesses with very 
different aetiology and treatment paradigms.  Cost information should therefore be published 
split by diabetes type so that researchers and decision makers can support the efficient and 
equitable allocation of diabetes resources.  The benefits of distinguishing costs by type of 
diabetes have been recognised in the literature for decades, for example Gerard et al [44] 
recognised that “it would be worthwhile to [distinguish between the various types of diabetes] 
as the types of costs and policies associated with each are likely to be different”.  However, it 
seems this recognition has not been translated into routine research methodology. 
 
The only formal COI study of Type 1 DM was published more than 15 years ago [8].  
Nationally available costing resources such as NHS Reference Costs were not available 
when the analysis was conducted and treatment pathways for Type 1 DM have changed 
significantly over the last 15 years with the advent of insulin analogues, intensive insulin 
therapy, CSII, and national recommendations regarding diabetes education [45].  These 
issues combine to render the resource use estimates from Gray et al [8] inadequate as 
estimates of current day consumption. 
 
There are two main approaches to COI studies: a prevalence-based approach that estimates 
the cost of illness of all prevalent cases over a defined period of time (often a year) and an 
incidence-based approach that follows an incident cohort of patients with the illness over 
their lifetimes.  All the studies reported here used annual prevalence-based methods.  
Incidence-based methods provide information about lifetime costs and therefore would offer 
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more insight into what costs could be saved if an intervention could prevent Type 1 DM [4] or 
what each patient costs the NHS over their lifetime. 
 
Resource use items were not generally included in analyses if Type 1 DM was a subsidiary 
diagnosis, therefore studies may underestimate the amount of healthcare resources 
consumed by Type 1 DM patients [46].  This is a particular problem as diabetes causes 
many severe complications which result in hospitalisations for which diabetes may not be 
recorded as the primary reason, despite it being the underlying cause [4].  Although ideally 
this resource use should be included in a COI study, the costs of diabetes as a subsidiary 
diagnosis have previously been extremely difficult to identify [44].  More recently the 
‘attributable risk’ approach has been used to identify the relative contribution of Type 1 DM 
to the risk of comorbid conditions (e.g. renal failure) [4].  Only one of the studies included in 
the review [35] used the attributable risk approach, to identify the proportion of prescription 
costs for non-diabetic medication that can be attributed to a patient having Type 1 DM. 
 
4.2. Heterogeneity between studies 
 
The published estimates of prevalence and cost of Type 1 DM vary greatly between sources.  
Comparison of cost estimates between studies was hindered due the disparate study 
designs, settings, populations, and data sources used in analyses.  For example, Gordois et 
al [34] estimated the annual cost of diabetic nephropathy as £200 million which is 
incongruous with the cost estimate from Gray et al [8] of £172 million for the whole of Type 1 
DM.  As an ‘official’ estimate of the cost of Type 1 DM is not available it falls on healthcare 
researchers to critically appraise published estimates.  The majority of studies [5, 32-38] 
focussed on a specific subset of diabetes care costs such as prescribing costs or the cost of 
a particular diabetic complication.  Due to their narrow scope these studies are unable to 
offer information on the total costs of Type 1 DM.  Gray et al [8] covered the whole of the 
Type 1 DM care programme but made many assumptions in calculating their estimates, 
including much generalisation from US data to the UK setting.  Their published figures were 
publicly criticised by Currie and Peters [30] as being significant underestimates of the true 
cost of Type 1 DM.  However, this criticism took the form of a letter and did not provide 
detailed information on how the authors’ estimates were calculated, hindering the 
assessment of their accuracy.  Currie et al [31] also provide disease-level cost estimates, 
however their costs come from an adult sample and as a proportion of the Type 1 DM 
population are under 18 [22] the cost estimates are unlikely to be representative of the whole 
population.  Their figures are also based on self-reporting of resource use which may be less 
accurate than estimates based on routinely collected resource use data such as medical 
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records.  The critical appraisal of the published cost estimates outlined above suggests that 
none of the available studies provide an accurate estimate of current costs of Type 1 DM in 
the UK.  As highlighted by Rice [47], “The reliability of [COI] study results depends on a 
variety of factors: the scope and recency of the study, the methodology used, and the 
sources of the data.” 
 
4.3. Limitations of our study 
 
The aim of the current study was to review existing evidence rather than to conduct a COI 
study therefore primary resource use and cost data sources were not searched.  Although 
no studies were identified that estimated the cost of cardiovascular disease in Type 1 DM 
patients, resource use data from Hospital Episodes Statistics (with cardiovascular disease 
and Type 1 DM as co-morbid diagnoses) and cost data from NHS Healthcare Resource 
Groups [48] and Reference Costs [49] could be obtained and combined to provide such an 
estimate.  However, this form of cost estimation was beyond the scope of the current study. 
 
Although the costs reported in the literature have been inflated to recent prices, they are 
unlikely to be accurate estimates of the current costs of Type 1 DM to the NHS.  Many 
factors other than inflation that are relevant to the cost of diabetes in the UK have changed 
over the last 15 years, some of which are outlined above. This study attempts to 
amalgamate evidence from across this period of time, from studies with differing designs, 
settings and scopes.  However, no new data were sought or collected, meaning that the 
inflated cost estimates reported do not reflect current treatment pathways or levels of 
resource use.  Provision of a more accurate estimate of the current cost of Type 1 DM in the 
UK would require a comprehensive COI study to collect up-to-date morbidity, resource use 




A recently published estimate of the cost of Type 1 DM in the UK was not identified from 
bibliographic databases or the grey literature therefore further research in the area is 






Future COI studies in the UK should: 
 
1. Estimate the costs of Type 1 DM separately from other diabetes types, as treatments 
and policies are not the same across diabetes types. 
 
2. Consider current treatment pathways to ensure that all treatment components, 
including newer developments in the care pathway such as insulin pumps and 
structured diabetes education, are included. 
 
3. Use unit cost figures published by national bodies such as the NHS Reference Costs 
[49] wherever possible. 
 
4. Use routinely collected resource use estimates wherever possible, for example the 
National Diabetes Audit (NDA) [22], as these will offer a more accurate 
representation of true resource use in the NHS than either self-report or resource use 
estimates from clinical trials. 
 
5. Include resource use where Type 1 DM is a subsidiary diagnosis as well as where 
diabetes is the primary diagnosis (the attributable risk approach could be used to 
support this aim). 
 
6. Use an incidence-based approach to provide information on the lifetime cost of Type 
1 DM patients (Pagano et al [25] highlight the importance of an incidence-based 
approach for providing a baseline against which new interventions can be assessed). 
 
7. Depending on the perspective of the COI study, attempt to quantify all types of costs 




The current published studies and grey literature on the costs of Type 1 DM in the UK fall 
short of providing accurate up-to-date estimates.  Many studies are outdated and diverse 
methodologies and populations have rendered comparisons between studies difficult.  The 
total cost of Type 1 DM in the UK is currently unclear, as cost and epidemiological data are 
available from a variety of sources, none of which provide a complete and comprehensive 
estimate.  There is a need for further research to update the published resource use and 
costing estimates of Type 1 DM in order to quantify the burden of Type 1 DM to the NHS.  
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Recommendations are made for a national, comprehensive COI study to address the 





J Kruger and A Brennan received funds to conduct this research from the Juvenile Diabetes 
Research Foundation.  We would like to acknowledge the help of Pippa Evans (School of 
Health and Related Research, University of Sheffield) in supporting the literature searches 






1. Department of Health: Research funding and priorities.  
http://www.dh.gov.uk/en/Aboutus/Researchanddevelopment/AtoZ/DH_4069152 
(2010). Accessed 10 April 2012 
 
2. BBC News: Diabetes and obesity rates on the rise, warns charity.  
http://www.bbc.co.uk/news/health-11605548 (2010). Accessed 10 April 2012 
 
3. Wilkinson, E.: Diabetes costs 'out of control'. http://www.bbc.co.uk/news/health-
10740224 (2010). Accessed 10 April 2012 
 
4. Ettaro, L., Songer, T., Zhang, P., Engelgau, M.: Cost-of-illness studies in diabetes 
mellitus. Pharmacoeconomics 22, 149-164 (2004) 
 
5. Currie, C., Peters, J.: Trends in the volume and cost of prescribing for diabetes. Br. J. 
Med. Econ. 8, 1-9 (1995) 
 
6. Donnan, PT., Leese, GP., Morris, AD.: Hospitalizations for People With Type 1 and 
Type 2 Diabetes Compared With the Nondiabetic Population of Tayside, Scotland. 
Diabetes Care 23, 1774-1779 (2000) 
 
7. Department of Health: Programme budgeting tools and data. 
http://www.dh.gov.uk/en/Managingyourorganisation/Financeandplanning/Programme
budgeting/DH_075743 (2012). Accessed 10 April 2012 
 
8. Gray, A., Fenn, P., McGuire, A.: The cost of insulin-dependent diabetes mellitus 
(IDDM) in England and Wales. Diabet. Med. 12, 1068-1076 (1995) 
 
9. Drummond, M., Sculpher, M., Torrance, G., O'Brien, B., Stoddart, G.: Methods for 
the Economic Evaluation of Health Care Programmes. Third edition. Oxford 
University Press, Oxford (2005) 
 
10. Scottish Intercollegiate Guidelines Network: Search Filters: Economic Studies.  




11. Department of Health: http://www.dh.gov.uk/en/index.htm (2012). Accessed 10 April 
2012 
 
12. Yorkshire and Humber Public Health Observatory: www.yhpho.org.uk (2012). 
Accessed 10 April 2012 
 
13. Scottish Public Health Observatory: www.scotpho.org.uk (2012). Accessed 10 April 
2012 
 
14. Public Health Wales: http://www.wales.nhs.uk/sitesplus/888/ (2012). Accessed 10 
April 2012 
 
15. Ireland and Northern Ireland's Population Health Observatory: 
http://www.inispho.org/ (2012). Accessed 10 April 2012 
 
16. The Information Centre: www.ic.nhs.uk (2012). Accessed 10 April 2012 
 
17. Diabetes UK: www.diabetes.org.uk (2012). Accessed 10 April 2012 
 
18. NHS Diabetes: www.diabetes.nhs.uk (2012). Accessed 10 April 2012 
 
19. National Institute for Health and Clinical Excellence: www.nice.org.uk (2012). 
Accessed 10 April 2012 
 
20. Diabetes.co.uk: www.diabetes.co.uk (2012). Accessed 10 April 2012 
 
21. Department of Health: Six years on: delivering the Diabetes National Service 
Framework.  
http://www.dh.gov.uk/en/Publicationsandstatistics/Publications/PublicationsPolicyAnd
Guidance/DH_112509 (2010). Accessed 10 April 2012 
 
22. The Information Centre: National Diabetes Audit. www.ic.nhs.uk/diabetesaudits 
(2012). Accessed 10 April 2012 
 
23. The Information Centre: Health Survey for England.  www.ic.nhs.uk/statistics-and-
data-collections/health-and-lifestyles-related-surveys/health-survey-for-england 




24. Wanless, D.: Securing Our Future Health: Taking a Long-Term View. HM Treasury, 
London (2002) 
 
25. Pagano, E., Brunetti, M., Tediosi, F., Garattini, L.: Costs of diabetes. A 
methodological analysis of the literature. Pharmacoeconomics 15, 583-595 (1999) 
 
26. Preferred Reporting Items for Systematic Reviews and Meta-Analyses: PRISMA 
2009 Checklist. http://www.prisma-statement.org/statement.htm (2009). Accessed 13 
July 2012 
 
27. Personal Social Services Research Unit: Unit Costs of Health and Social Care 2010. 
Compiled by Lesley Curtis, ed. University of Kent, Canterbury (2010) 
 
28. National Institute for Health and Clinical Excellence: Continuous subcutaneous 
insulin infusion for the treatment of diabetes mellitus: Review of technology appraisal 
guidance 57 (2008) 
 
29. Yorkshire and Humber Public Health Observatory: APHO Diabetes Prevalence 
Model.  http://www.yhpho.org.uk/default.aspx?RID=81090 (2011). Accessed 10 April 
2012 
 
30. Currie, C., Peters, J.: Costs of insulin-dependent diabetes mellitus. Diabet. Med. 13, 
684-685 (1996) 
 
31. Currie, CJ., Poole, CD., Woehl, A., Morgan, CL., Cawley, S., Rousculp, MD., et al.: 
The financial costs of healthcare treatment for people with Type 1 or Type 2 diabetes 
in the UK with particular reference to differing severity of peripheral neuropathy. 
Diabet. Med. 24, 187-194 (2007) 
 
32. Hammer, M., Lammert, M., Mejias, SM., Kern, W., Frier, BM., Hammer, M., et al.: 
Costs of managing severe hypoglycaemia in three European countries. J. Med. 
Econ. 12, 281-290 (2009) 
 
33. Leese, GP., Wang, J., Broomhall, J., Kelly, P., Marsden, A., Morrison, W., et al.: 
Frequency of severe hypoglycemia requiring emergency treatment in type 1 and type 
22 
 
2 diabetes: a population-based study of health service resource use. Diabetes Care 
26, 1176-1180 (2003) 
 
34. Gordois, A., Scuffham, P., Shearer, A., Oglesby, A., Gordois, A., Scuffham, P., et al.: 
The health care costs of diabetic nephropathy in the United States and the United 
Kingdom. J. Diabetes Complicat. 18, 18-26 (2004) 
 
35. Evans, JM., MacDonald, TM., Leese, GP., Ruta, DA., Morris, AD.: Impact of type 1 
and type 2 diabetes on patterns and costs of drug prescribing: a population-based 
study. Diabetes Care 23, 770-774 (2000) 
 
36. Poole, C., Tetlow, T., McEwan, P., Holmes, P., Currie, CJ.: The prescription cost of 
managing people with type 1 and type 2 diabetes following initiation of treatment with 
either insulin glargine or insulin detemir in routine general practice in the UK: A 
retrospective database analysis. Curr. Med. Res. Opin. 23, S41-S48 (2007) 
 
37. Colquitt, JL., Green, C., Sidhu, MK., Hartwell, D., Waugh, N.: Clinical and cost-
effectiveness of continuous subcutaneous insulin infusion for diabetes. Health 
Technol. Assess. 8, iii-171 (2004) 
 
38. Feltbower, RG., Campbell, FM., Bodansky, HJ., Stephenson, CR., McKinney, PA.: 
Insulin pump therapy in childhood diabetes-cost implications for Primary Care Trusts. 
Diabet. Med. 23, 86-89 (2006) 
 
39. Office for National Statistics: Annual Mid-year Population Estimates, 2010. 
http://www.ons.gov.uk/ons/rel/pop-estimate/population-estimates-for-uk--england-
and-wales--scotland-and-northern-ireland/mid-2010-population-estimates/annual-
mid-year-population-estimates--2010.pdf (2011). Accessed 13 July 2012. 
 
40. de Lusignan, S., Khunti, K., Belsey, J., Hattersley, A., van Vlymen, J., Gallagher, H., 
et al.: A method of identifying and correcting miscoding, misclassification and 
misdiagnosis in diabetes: a pilot and validation study of routinely collected data. 
Diabet. Med. 27, 203-209 (2010) 
 
41. Gray, J., Ekins, M., Scammell, A., Carroll, K., Majeed, A.: Workload implications of 
identifying patients with ischaemic heart disease in primary care: population-based 




42. de Lusignan, S., Gallagher, H., Chan, T., Thomas, N., Van Vlymen, J., Nation, M.: 
The QUICKD study protocol: a cluster randomised trial to compare quality 
improvement interventions to lower systolic BP in chronic kidney disease (CKD) in 
primary care. Implement. Sci. 4, 39 (2009) 
 
 
43. National Institute for Health and Clinical Excellence: Diabetes - insulin pump therapy: 
costing template.  http://guidance.nice.org.uk/TA151/CostingTemplate/xls/English 
(2010). Accessed 10 April 2012 
 
44. Gerard, K., Donaldson. C., Maynard, A.: The cost of diabetes. Diabet. Med. 6, 164-
170 (1989) 
 
45. National Institute for Health and Clinical Excellence: Guidance on the use of patient-
education models for diabetes (2003) 
 
46. Simell, TT., Sintonen, H., Hahl, J., Simell, OG.: Costs of insulin-dependent diabetes 
mellitus. Pharmacoeconomics 9, 24-38 (1996) 
 
47. Rice, D.: Cost of illness studies: what is good about them? Inj. Prev. 6, 177-179 
(2000) 
 
48. The Information Centre: Healthcare Resource Groups 4 (HRG4).  
http://www.ic.nhs.uk/services/the-casemix-service/new-to-this-service/healthcare-
resource-groups-4-hrg4 (2012). Accessed 10 April 2012 
 
49. Department of Health: NHS reference costs 2009-2010.  
http://www.dh.gov.uk/en/Publicationsandstatistics/Publications/PublicationsPolicyAnd




Table 1 Published studies included in the review 





1995 Trends in the volume and 










Gray et al 
[8] 
1995 The cost of insulin-dependent 
diabetes mellitus (IDDM) in 




















2000 Impact of type 1 and type 2 
diabetes on patterns and 












2003 Frequency of Severe 
Hypoglycaemia Requiring 
Emergency Treatment in 
Type 1 and Type 2 Diabetes 
Cost-of-
illness 
Scotland Direct cost of 
hypoglycaemia 
Colquitt 
et al [37] 
2004 Clinical and cost-
effectiveness of continuous 









et al [34] 
2004 The health care costs of 
diabetic nephropathy in the 







Direct cost of 
nephropathy 
Feltbower 
et al [38] 
2005 Insulin pump therapy in 
childhood diabetes-cost 










2007 The financial costs of 
healthcare treatment for 
people with Type 1 or Type 2 
diabetes in the UK with 
particular reference to 














2007 The prescription cost of 
managing people with type 1 
and type 2 diabetes following 
initiation of treatment with 
either insulin glargine or 
insulin detemir in routine 





UK Direct cost of 
insulin glargine 
Hammer 
et al [32] 
2009 Costs of managing severe 













Table 2 Breakdown of costs of Type 1 DM in England & Wales in 1992, as reported by Gray 
























23.1 11.0 0.7 12.5   47.3 
Vascular 
complications 
 4.5 0.1 0.1   4.8 
Ophthalmic 
complications 
 1.0 0.06 0.04   1.11 
Neurological 
complications 
 1.2 0.03 0.03   1.2 
Renal 
complications 
 3.5 0.1 0.09  26.5 30.2 
Total cost 23.1 21.1 1.0 12.8 11.0 26.5 95.6 
Percent 24.2% 22.1% 1.1% 13.3% 11.5% 27.7% 100% 




Table 3 Studies identified in the review, by diabetic complication 
 
Complication Studies 
Nephropathy Gordois et al [34] 
Peripheral neuropathy Currie et al [31] 
Autonomic neuropathy - 
Retinopathy - 
Cardiovascular disease - 
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published 
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social care system 
Gray et al [8] 
 
1992 England & 
Wales 
£95,600,000 £175,436,170a 
Total direct annual cost to health and 
social care system 
Currie & Peters 
[30] 
1994/95 England & 
Wales 
£180,000,000 £311,278,195 
Total annual cost per patient Currie et al [31]  2005 Wales £3,224 £3,694 
Insulin Routine insulin maintenance Gray et al [8] 1992 England & 
Wales 
£23,100,000 £42,390,957 
Annual cost of glargine per person Poole et al [36] 2004 UK £1,198 £1,423 
Annual cost of detemir per person Poole et al [36] 2004 UK £1,330 £1,580 
Insulin pumps Annual cost of implementing CSII NICE [28] 2007/08 England £24,605,000 £26,424,047 
Annual cost of CSII if 1% of Type 1 
patients use it 
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patients use it 
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1992 England & 
Wales 
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In-patient costs (per patient) Currie et al [31]  2005 Wales £1,294 £1,483 
Out-patient costs (per patient) Currie et al [31]  2005 Wales £655 £750 
Nurse costs (per patient) Currie et al [31]  2005 Wales £53 £61 
GP costs GP costs Gray et al [8] 
 
1992 England & 
Wales 
£1,000,000 £1,835,106 
GP costs (per patient) Currie et al [31]  2005 Wales £173 £198 
Hypoglycaemia 
costs 
Direct costs of severe 
hypoglycaemia 
Leese et al [33] 1997/98 UK £6,000,000 £9,544,669 
Cost of severe hypo (family/domestic 
setting) 




UK £37 £40 
Cost of severe hypo (community 
HCP setting) 




UK £256 £275 
Cost of severe hypo (hospital HCP 
setting) 




UK £887 £953 
Nephropathy 
costs 
Renal replacement therapy Gray et al [8] 
 
1992 England & 
Wales 
£26,500,000 £48,630,319 
Total cost of nephropathy in Type 1 
DM 
Gordois et al 
[34] 
2001 UK £152,000,000 £203,157,385 
Other costs Social security non-transfer 
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Appendix 1 Studies excluded at the full text stage 
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1208-12 
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Gerard et al 
(1989) 
Gerard K, Donaldson C, Maynard AK. The cost of diabetes. Diabetic Medicine 1989; 
6:164-170. 
Does not split costs by diabetes type 
Boren (2009) Boren SA, Fitzner KA, Panhalkar PS, Specker JE, Boren SA, Fitzner KA, et al. Costs 
and benefits associated with diabetes education: a review of the literature. Diabetes 
Educator 2009;35(1):72-96. 
No UK-specific data and does not split 
by diabetes type 
Bottomley 
(2007) 
Bottomley JM, Raymond FD, Bottomley JM, Raymond FD. Pharmaco-economic 
issues for diabetes therapy. Best Practice & Research Clinical Endocrinology & 
Metabolism 2007;21(4):657-85. 
Focus is on type 2 diabetes and does 
not report UK data 
Boutayeb 
(2004) 
Boutayeb AT. A mathematical model for the burden of diabetes and its 
complications. BioMedical Engineering Online 2004;3:28. 
Does not split by diabetes type 
Chukwuma 
(1993) 
Chukwuma C, Sr., Chukwuma CS. Type I diabetic nephropathy: clinical 
characteristics and economic impact. Journal of Diabetes & its Complications 
1993;7(1):15-27. 
No UK information on prevalence or 
costs 
Icks (2007) Icks A, Holl RW, Giani G, Icks A, Holl RW, Giani G. Economics in pediatric Type 1 
DM - results from recently published studies. Experimental & Clinical Endocrinology 
& Diabetes 2007;115(7):448-54. 
Literature review of paediatric Type 1 





Jendle (2009) Jendle JH. Resource utilisation and costs for the treatment of diabetes in the 
developed world: An economical burden that needs to be solved. International 
Journal of Clinical Practice 2009;63(7):997-1007 




Laing W, Williams R. Diabetes: A model for health care management. Office of 
Health Economics, London 1989. 
No primary data and not split by 
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Leese (1992) Leese B, Leese B. The costs of diabetes and its complications. Social Science & 
Medicine 1992;35(10):1303-10. 
No primary data and not split by 
diabetes type 
Mallick (1996) Mallick NPD. The changing population on renal replacement therapy: Its clinical and 
economic impact in Europe. Nephrology Dialysis Transplantation 1996;11(SUPPL. 
2):2-5 
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no cost data 
Milton (2006) Milton B, Holland P, Whitehead M, Milton B, Holland P, Whitehead M. The social and 
economic consequences of childhood-onset Type 1 DM mellitus across the 
lifecourse: a systematic review. Diabetic Medicine 2006;23(8):821-9. 
Does not report cost data 
Morris (2002) Morris AD. Considerations in assessing effectiveness and costs of diabetes care: 
Lessons from DARTS. Diabetes/Metabolism Research and Reviews 
2002;18(SUPPL. 3): S32-5 
No Type 1-specific results presented 
Narins (1988) Narins BE, Narins RG, Narins BE, Narins RG. Clinical features and health-care costs 
of diabetic nephropathy. Diabetes Care 1988;11(10):833-9. 




Palmer (2004) Palmer AJ, Roze S, Valentine WJ, Minshall ME, Foos V, Lurati FM, et al. The CORE 
Diabetes Model: Projecting long-term clinical outcomes, costs and cost-effectiveness 
of interventions in diabetes mellitus (types 1 and 2) to support clinical and 
reimbursement decision-making. Current Medical Research & Opinion 2004;20 
Suppl 1:S5-26. 
Description of a cost-effectiveness 
model; no cost results reported 
Rippin (2004) Rippin JDB. Cost-Effective Strategies in the Prevention of Diabetic Nephropathy. 
Pharmacoeconomics 2004;22(1):2004. 
No cost-of-illness data reported 
Salas (2009) Salas M, Hughes D, Zuluaga A, Vardeva K, Lebmeier ME-MA, Salas Mmue. Costs of 
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Simell (1993) Simell T, Simell O, Sintonen H, Simell T, Simell O, Sintonen H. The first two years of 
Type 1 DM in children: length of the initial hospital stay affects costs but not 
effectiveness of care. Diabetic Medicine 1993;10(9):855-62. 
Costs in GBP£ but study took place in 
Finland 
Simell (1996) Simell TT, Sintonen H, Hahl J, Simell OG, Simell TT, Sintonen H, et al. Costs of 
insulin-dependent diabetes mellitus. Pharmacoeconomics 1996;9(1):24-38. 
No UK-specific data reported 
Skyler (2000) Skyler JS, Skyler JS. The economic burden of diabetes and the benefits of improved 
glycemic control: the potential role of a continuous glucose monitoring system. 
Diabetes Technology & Therapeutics 2000;2 Suppl 1:S7-12. 
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Trueman P, Taylor M, Twena N, Chubb B, Trueman P, Taylor M, et al. The cost of 
needlestick injuries associated with insulin administration. British Journal of 
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Does not split by diabetes type 
Yao (2006) Yao GA, Albon E, Adi Y, Milford D, Bayliss S, Ready A, Raftery J, Taylor RS. A 
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1 exp diabetes mellitus, insulin dependent/ 
2 exp Diabetic Ketoacidosis/ 
3 IDDM.tw. 
4 (insulin? depend$ or insulin?depend$).tw. 
5 ((typ$ 1 or typ$ I) adj diabet$).tw. 
6 (earl$ adj diabet$).tw. 
7 ((juvenil$ or child$ or keto$ or Labil$ or brittl$) adj diabet$).tw. 
8 ((auto?immun$ or sudden onset) adj diabet$).tw. 
9 (insulin? defic$ adj absolut$).tw. 
10 1 or 2 or 3 or 4 or 5 or 6 or 7 or 8 or 9 
11 exp diabetes insipidus/ 
12 diabet$ insipidus.tw. 
13 11 or 12 





2 "costs and cost analysis"/ 
3 Cost allocation/ 
4 Cost-benefit analysis/ 
5 Cost control/ 
6 Cost savings/ 
7 Cost of illness/ 
8 Cost sharing/ 
9 "deductibles and coinsurance"/ 
10 Medical savings accounts/ 
11 Health care costs/ 
12 Direct service costs/ 
13 Drug costs/ 
14 Employer health costs/ 
15 Hospital costs/ 
16 Health expenditures/ 
17 Capital expenditures/ 
18 Value of life/ 
19 Exp economics, hospital/ 
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22 Economics, pharmaceutical/ 
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